Grey’s Anatomy: What Happened To Katherine Heigl’s Izzie – Screen Rant

Grey's Anatomy finally gave closure to Katherine Heigl's Izzie Stevens in season 16 and here's what happened after Heigl left the show.

Greys Anatomy gave Katherine Heigl worldwide recognition thanks to her role as Izzie Stevens, but what happened to her after Heigls departure from the series? Created by Shonda Rhimes, Greys Anatomy debuted on ABC in 2005 and has been unstoppable ever since. The series was originally a mid-season replacement, but it was very well received by critics and audiences, which has allowed it to continue for years.

Like any other medical drama, Greys Anatomy follows the lives of surgical interns, residents, and attendings, who do their best to balance their professional and personal lives. The series is set in Seattle, at the fictional Seattle Grace Hospital (later Seattle Grace Mercy West Hospital), and is led by Meredith Grey (Ellen Pompeo), who along with Miranda Bailey (Chandra Wilson) and Richard Webber (James Pickens Jr) are the only characters from season 1 who are still part of the show. Greys Anatomy is now waiting for its 17th season, and season 16 saw another character from season 1 leave: Alex Karev (Justin Chambers), whose departure ended up revealing the fate of another character.

Related: Best TV Shows Of The Decade

Izzie Stevens, just like Meredith and Alex, started out as an intern at Seattle Grace Hospital, and grew close with Alex, with whom she had an on-again off-again relationship. When Izzie discovered she had cancer, Meredith suggested she had healthy eggs removed from her in case she wanted to have kids in the future, and she did so. Her treatment was complicated, and after discovering another tumor in her brain, Meredith and Derek gave away their wedding to Izzie and Alex, and so they got married. Izzie got better and went back to work, but was fired after giving the wrong dosage of medicine to a patient. Thinking Alex was partly to blame, she wrote him a letter and left, but later returned for a final PET scan and to ask Derek to write her a recommendation letter so she could get a job in Tacoma. After that, her relationship with Alex was broken, and she left.

Izzie later sent divorce papers to Alex, which he signed, and they moved on, though they still had feelings for each other. Season 16 of Greys Anatomy finally revealed what happened to her after leaving Seattle: Alex explained that when Meredith was about to lose her license, he reached out to Izzie so she could help her. He admitted it was an excuse to finally call her, and thats how he learned that Izzie has twins and they are also his. Alex leaves Seattle to live with Izzie and their children in Kansas, as she was a single mother. Izzie carried on with her career and is now a surgical oncologist, and she and Alex are shown to be building a life together as a family.

The scenes showing Izzie and Alexs new life were possible thanks to stand-ins, as neither Heigl nor Chambers returned for that (Chambers only lent his voice in this episode). Fan reaction to Izzies fate in Greys Anatomy was mixed: some liked that she was given a happy ending after all she went through, even if how it was portrayed wasnt exactly the best way to do it, while others feel it was disrespectful to their stories to have them end up like this, but at least the writers finally gave proper closure to her arc.

Next: What Happened To Katherine Heigl

Every Reveal About The Arrowverse's Batman (So Far)

Adrienne Tyler is a features writer for Screen Rant. She is an Audiovisual Communication graduate that wanted to be a filmmaker, but life had other plans (and it turned out great). Prior to Screen Rant, she wrote for Pop Wrapped, 4 Your Excitement (4YE), and D20Crit, where she was also a regular guest at Netfreaks podcast. She was also a contributor for FanSided's BamSmackPow and 1428 Elm. Adrienne is very into films and she enjoys a bit of everything: from superhero films, to heartbreaking dramas, to low-budget horror films. Every time she manages to commit to a TV show without getting bored, an angel gets its wings.

When she's not writing, you can find her trying to learn a new language, watching hockey (go Avs!... But also Caps and Leafs), or wondering what life would have been like had Pushing Daisies, Firefly, and Limitless not been cancelled. Breakfast food is life and coffee is what makes the world go round.

Guillermo del Toro said hi to her once. It was great.

"Vnligheten r ett sprk som de dva kan hra och de blinda kan se".

Originally posted here:
Grey's Anatomy: What Happened To Katherine Heigl's Izzie - Screen Rant

Early Thor Concept Art Imagines Grey’s Anatomy’s Kevin McKidd In The MCU – Screen Rant

Newly resurfaced Thor concept art is based on Grey's Anatomy's Kevin McKidd, who was in the running before Chris Hemsworth landed the part.

Recently resurfacedThorconcept art imaginesGrey's Anatomyactor Kevin McKidd as the Marvel hero. Since his debut in his 2011 solo film, Thor has become a vital part of the Marvel Cinematic Universe. Though the second film in his standalone series,Thor: The Dark World, was a critical disappointment, he bounced back withThor: Ragnarok. It provided a lighter take on the character and segued into his relationship with the similarly eccentric Guardians of the Galaxy. Now, it's hard to imagine anyone but Chris Hemsworth in the role, as he's navigated Thor's character development with ease. However, Hemsworth wasn't the only actor up for the role.

At one point, McKidd was reportedly in the running for Thor. This was back in 2008, around the time McKidd joinedGrey's Anatomyas Owen Hunt. Though he didn't wind up getting the part of Thor, McKidd did eventually play a god, starring inPercy Jackson & the Olympians: The Lightning Thief as Poseidononly a couple years later. Another actor who nearly played Thor is Daniel Craig, who wasn't able to because of his role as James Bond. Other actors considered include Channing Tatum, Charlie Hunnam, and even Liam Hemsworth.

Related:Avengers: Actors Who Almost Played The Original 6 Heroes

Because so many actors were up for the role, it makes sense early concept art varied. Marvel Studios Visual Development co-founderCharlie Wen shared someThorconcept art on Instagram today, which was based on McKidd. The art was previously featured inThe Art of Thor, a Marvel artbook released in 2011. Check it out below:

It makes sense Wen specifies the art was based on McKidd rather than being a carbon copy. It only loosely looks like the actor, especially ten plus years after it was created. However, it does give a good idea of what McKidd might have looked like then with Thor's trademark long locks. Though McKidd didn't end up getting the Thor gig, it's not as though his career has tanked since. He's remained a fixture in the entertainment industry thanks to his ongoingGrey's Anatomyrole. At this point, he's even outlasted several original cast members.

All told, theThorconcept art offers a fascinating reminder of the complicated design process for superhero films. Not only do artists have to create a look for the character, they also have to take into consideration whichever actors are up for the role. Though it's interesting to see the basis for what McKidd might have looked like as Thor, it feels like the right person wound up with the role.

More:Avengers: Age of Ultron Foreshadowed Thors Infinity War Failure

Source: Charlie Wen

Key Release Dates

Terminator: Dark Fate Star Admits Fans Dont Want A Sequel

Rebecca VanAcker is a news writer and evening editor at Screen Rant. She enjoys covering all things superhero, especially Marvel and the Arrowverse. In the past, shes written TV recaps for Screen Picks and reviews for Yahoo TV UK. Though Rebecca likes movies and other forms of storytelling, TV is her true passion, having written about it in some capacity since 2014. She especially loves female-driven shows like Parks and Recreation, Jane the Virgin, and Fleabag. A graduate of Michigan State University, Rebecca got her teaching certificate before falling in love with writing and the entertainment industry. She has a B.A. in English, and her longtime love of reading has followed her into adulthood. While she enjoys discovering new books, right now shes probably just re-reading Harry Potter for the millionth time. Her other hobbies include baking, anything Disney, and exploring with her dog, Beckett. You can follow Rebecca on Twitter @BecksVanAcker, or contact her directly at rvanacker23(at)gmail(dot)com.

Read more:
Early Thor Concept Art Imagines Grey's Anatomy's Kevin McKidd In The MCU - Screen Rant

CX 2020 LIVE: Surgeon-modified and custom-made endografts carve their place in juxtarenal aneurysm treatment – Vascular News

Clockwise from top left: Roger Greenhalgh (London, UK), Stphan Haulon (Paris, France), Gustavo Oderich (Rochester, USA), Nikolaos Tsilimparis (Munich, Germany), Bijan Modarai (London, UK) and Said Abisi (London, UK). Click on the image to watch the Juxtarenal Aneursym Consesus session on demand.

During the last five weeks,CX 2020 LIVEhas attracted over 6,000 registrants from more than 120 countries.The topic of the 10th and final session was Juxtarenal Aneurysm Consensus. Experts covered cutting-edge developments in the field and tips and tricks for complex procedures. They also examined outcomes with a range of devices on the market.There was lively discussion reviewing surgeon-modified and custom-made fenestrated endografts and strong support for inner branch technology, backed by 79% of participants. Other topics covered include bridging stent grafts, balloon-expandable covered bridging stents, and off-the-shelf solutions for hostile necks. The session was chaired by Stphan Haulon (Paris, France) and moderated by Gustavo Oderich (Rochester, USA), who cautioned against being a staunch defender of one technique over another, as everything has a potential role.

Said Abisi (London, UK) reported on experience with inner branch technologies and noted that although endovascular aneurysm repair (EVAR) and branched endovascular aneurysm repair (BEVAR have good outcomes, they are limited by certain anatomical challenges which can make these procedures difficult. Fenestrated procedures in particular require very accurate planning and positioning, and vessel deformation due to infrarenal angulation and iliac tortuosity may result in unpredictable outcomes, he adds. In addition, traditional BEVAR with outer branches requires enough working lumen for the branches to open out and also requires long aortic coverage and a longer distance for bridging stents.

The researchers set out to examine a cohort of patients undergoing fenestrated and branched EVAR over the past two years, focusing on procedural outcomes to investigate the indications for use of inner branches.

Abisi summarised that inner branches have a good early outcome for the treatment of highly complex aortic aneurysms, adding that they are easy to use, adaptable to variable anatomy, and have demonstrable advantages compared to conventional technology. However, he noted that longer-term data are needed to determine their wider applicability.

Responding to a question from Oderich regarding patency concerns, Abisi outlined that this is why we are currently very cautious about selecting only those who are not suitable for standard fenestrated or branched, and concluded that, as a result, the data need to be monitored, with patients followed-up over the long term.

Tips and tricks for repairing a thoracoabdominal aortic aneurysm using an off-the-shelf device

Bijan Modarai (London, UK) presented a case that demonstrated the repair of a large thoracoabdominal aortic aneurysm using an off-the-shelf thoracoabdominal branched device. The Zenith t-Branch (Cook Medical) incorporates four downward-facing outer branches and is designed to be coupled in a modular fashion with proximal and distal components to allow treatment of a variety of aortic anatomies. Modarai noted that a number of markers on the stent graft facilitate accurate positioning, once it is placed inside the aorta. He described the techniques adopted, which ultimately led to successful sealing of the aneurysm.

Asked about what the best strategy is for preventing bridging stent failure, Modarai answered that the mode of failure is multifactorial. I do not think it is about saying whether it is best to use a balloon-expandable or self-expandable stent. I think it comes down to good quality control. He went on to explain that this means adequate sizing; ensuring that those branches are positioned in the optimal way so that the bridging distance is not very long; ensuring that the stent is [far] enough inside the branch so that there is adequate overlap, and to make sure that the stent is not too far deep into the target vessel.

In regards to the use of antiplatelet therapy, Modarai stated that because we do not have level one evidence, I tend to put these patients for at least a year, if not for life, on dual antiplatelet agents in the hope that all of those measures will reduce the chances of a stent occlusion but commented that a mistake that a lot of people make is to compare branches with fenestrations, which he said is like comparing apples with oranges.

A further question on the spinal complication rate, which Modarai highlighted was the most feared complication with these repairs, and how best to prevent it, led Modarai to remark that the rate of cord complication is related to the amount of the aorta that is covered. In terms of prevention, Modarai asserted that again, I think it is multifactorial; some of the repairs are worth staging.

Custom-made fenestrated endografts are first source for elective repair, but surgeon modification useful in emergencies

Nikolaos Tsilimparis (Munich, Germany) offered an insight into the technical success achieved through surgeon-modified fenestrated endografts compared to custom-made fenestrated endografts. His presentation revealed that surgeon-modified endografts have been associated with higher type 3 endoleaks and reintervention, but achieve similar long-term outcomes to the custom-made devices.

However, Tsilimparis noted that to directly measure up the two treatment options side-by-side could be seen as an unfair comparison, commenting that they are two different entities. In particular, he highlighted the role physician-modified endografts have to play in urgent aortic repairs, adding that custom-made devices should be seen as the first source for elective repair. This conclusion was echoed by Oderich who commented that he had raised a very important point, which is that sometimes you are in a tight spot where you cannot use an off the shelf device, or, it is not in the best interests of the patient.

Oderich asked Tsilimparis for his thoughts on the importance of gaining experience with FEVAR in general, and the importance of quality control in modifying a device, particularly with regard to sizing and planning. Tsilimparis commented that many surgeons had made the mistake of trying to learn the fenestrated endograft technique and how to modify the device simultaneously, rather than opting to use custom-made devices initially. This is a big challenge when you try to do both at once, Tsilimparis added. It is important in my eyes to start with easy cases with custom-made devices, and really rely on surgeon-modified [devices] if you have the experience with these, and also if you feel very comfortable with the stent grafts and the technique overall.

An audience member from India asked Tsilimparis why he felt there was a higher rate of type 3 endoleaks seen in surgeon-modified, compared to custom-made devices. Tsilimparis replied that there were some technical aspects to explain this disparity, including some differences in sealing techniques between both device types. He also commented that, often, surgeon-modified endografts may be used in cases where there is a further distance between the aortic wall to the stent graft, citing this as another possible cause.

New generation of bridging stent grafts addresses flexibility and deliverability

Following Tsilimparis, Eric Verhoeven (Nuremberg, Germany) then detailed his centres experience of the use of a new generation of bridging stent graftsthe BeGraft and BeGraft+ (Bentley), the former for use in fenestrations, and the latter in branched procedures. Verhoeven told the CX 2020 LIVE audience that these latest devices have a higher radial force than earlier generations, as well as an increased kink resistance.

Summarising his experience, Verhoeven welcomed the development of the new generation devices. He added: The transition with the target vessel is something to watch and sometimes you have to reline, and sometimes extend with a self-expandable stent to smoothen the transition zone.

Haulon remarked that he was surprised to see that everyone today is using balloon-expandable stents, to which Oderich concurred, adding and I think that reflects significant improvementby the industry to address the issue of flexibility of these stents and deliverability through a small profile.

Following Verhoevens presentation, polling revealed that 79% of the audience like the idea of using inner branched technology, with Haulon commenting: It seems that everyone believes that it is an interesting idea to use inner branches, so we need to evaluate those and hopefully we will have data to support the use of this new design in the near future.

Best balloon-expandable covered bridging stent depends on surgeon preference, target artery anatomy

Mauro Gargiulo (Bologna, Italy) compared a range of balloon-expandable covered bridging stents (BECS) for fenestrated and branched endovascular aneurysm repair procedures.

On the current indications for using BECS for fenestration, Gargiulo stated: All of us agree that the balloon-expandable stent graft is the choice, according to long-term results reported in the literature.

Regarding branched procedures, Gargiulo noted that while some literature indicates no difference in occlusion or reintervention comparing balloon-expandable and self-expandable stents, other work favours the self-expandable graft for these procedures.

In our centre, we use a balloon-expandable stent graft in all target artery anatomy expect renal arteries type B and D, Gargiulo reported, adding that a hybrid approach, with a self-expandable balloon distally and a balloon-expandable stent proximally results in an increase of renal artery patency and is a good option for type B and type D renal arteries.

Gargiulo then listed ideal features of a stent graft, including navigability, visibility, precise deployment, conformability, radial force, flaring attitude, and patency.

Considering the structural features and biomechanical properties of various devices on the market, Gargiulo summarised: The advantages of the iCAST/V12 [Getinge] are the precise deployment and the proven long-term results; the BeGraft , its good trackability, high flexibility, and the compatibility with the 6Fr sheath; and the VBX [Gore], its high flexibility, heparin-bonded bioactive surface, good trackability, and wide range of lengths.

I do not think there is a best BECS for all occasions, Gargiulo concluded. He detailed that for fenestration, surgeon preference, the aortic endograft device, and the target artery anatomy are all important factors, and for branched procedures, the surgeons preference, the cannulation of the branch from either brachial or femoral access, and the target artery anatomy are key.

Off-the-shelf endovascular solutions for the treatment of AAAs with a hostile neck

Jean-Paul de Vries (Groningen, the Netherlands) told the CX 2020 LIVE audience how to achieve durability with off-the-shelf solutions for the treatment of abdominal aortic aneurysms (AAAs) with a hostile neck while minimising hospital resource impact.By evaluating the seal zone of the three types of aortic necksadequate, hostile, and inadequateone can isolate the different needs in those necks and patients, de Vries noted.

He stated that, for the adequate neck, you only need seal, whereas in the hostile neck, you need additional strength, and in the inadequate neck, you need also to extend the seal to the juxtarenal or suprarenal aorta.

He recommended using the gold standard of endovascular aneurysm repair (EVAR) when there is an adequate seal zone, endosuture aneurysm repair (ESAR) in hostile necks , and a fenestrated or chimney device in an inadequate neck. With a chimney device, the advantage is there is no waiting time, it is off-the-shelf, and the total costs are lower compared to fenestrated devices. However, it is limited to a maximum of two chimneys, de Vries told the audience.

Follow this link:
CX 2020 LIVE: Surgeon-modified and custom-made endografts carve their place in juxtarenal aneurysm treatment - Vascular News

UW researchers publish on the decline of the Western bumblebee – Oil City News

Christy Bell, a Ph.D. student in the UW Department of Zoology and Physiology, observes a Western bumblebee. Bell and Lusha Tronstad, lead invertebrate zoologist with the Wyoming Natural Diversity Database, are co-authors of a paper about Western bumblebees. (Christy Bell)

CASPER, Wyo A University of Wyoming (UW) researcher and her Ph.D. student have spent the last three years studying the decline of the Western bumblebee. Their paper, titledWestern Bumble Bee: Declines in the United States and Range-Wide Information Gaps,was published online June 26 inEcosphere, according to a UW release Monday. The journal publishes papers from all subdisciplines of ecological science.

Lusha Tronstad, lead invertebrate zoologist with the Wyoming Natural Diversity Database (WYNDD), and Christy Bell, her Ph.D. student in the Department of Zoology and Physiology, have been working with a group of bumblebee experts to fill in gaps of missing information from previous data collected in the western United States. Their goal is to provide information on the Western bumblebee to the U.S. Fish and Wildlife Service while it considers listing this species under the U.S. Endangered Species Act, the university release said.

Tronstad and Bell are members of the Western Bumble Bee Working Group, a group of experts on the species which came together to pool knowledge on the species, Tronstad said. The paper highlights knowledge gaps, specifically the lack of sampling data in Alaska, northwestern Canada and the southwestern United States.

Article continues below...

The data we assembled will be used by the U.S. Fish and Wildlife Service to inform its decision on whether or not to protect the Western bumblebee under the U.S. Endangered Species Act, Tronstad said.At WYNDD our mission is to provide the most up-to-date data on which management decisions can be based.

The decline of the Western bumblebee is likely not limited to one culprit but, instead, due to several factors that interact such as pesticides, pathogens, climate change and habitat loss, said Tronstad. Western bumblebees were once the most abundant bumblebees on the West Coast of the U.S., but they are much less frequently observed there now. Pathogens (or parasites) are thought to be a major reason for their decline.

Tronstad said there are several things that homeowners or landowners can do to help this species of bumblebee survive and thrive.These include:

Tronstad said Bells research will continue this summer.

Read the full UW release here.

Other contributors to the paper are from the U.S. Geological Survey; U.S. Fish and Wildlife Service; Canadian Wildlife Service; Xerces Society for Invertebrate Conservation in Portland, Ore.; British Columbia Ministry of Environment and Climate Change Strategy; University of Hawaii-Hilo; U.S. Department of Agriculture; The Institute for Bird Populations; University of Vermont; Utah State University; Ohio State University; Denali National Park and Preserve; and the Royal Saskatchewan Museum.

Related Stories from Oil City News:

More:
UW researchers publish on the decline of the Western bumblebee - Oil City News

Yale researchers find on-off switch for inflammation related to overeating – Yale News

Researchers at Yale have identified a molecule that plays a key role in the bodys inflammatory response to overeating, which can lead to obesity, diabetes, and other metabolic diseases. The finding suggests that the molecule could be a promising therapeutic target to control this inflammation and keep metabolic diseases in check.

The study appears on June 29 in the Proceedings of the National Academy of Sciences.

When a person overeats, the body stores excess calories in the form of fat in the adipose tissue, or body fat, said lead author Xiaoyong Yang of Yale School of Medicine. As the amount of calories consumed continues to increase, this leads to inflammation in adipose tissue and the release of fatty acids into other tissues, including the liver and muscles.

This is dangerous, Yang said, and leads to metabolic disorders like diabetes.

Researchers were aware that overeating led to inflammation and metabolic diseases, but until now, they did not know the precise way that the bodys immune cells, such as macrophages which react to excess calorie consumption contributed to this process. The new research by Yang and team zeroed in on a pathway called O-GIcNAc signaling, which activates when a person overeats, instructing the cells to limit inflammation.

Inflammation happens when the bodys immune system reacts to injury or threat, and involves increased blood flow, capillary dilation, and an influx of white blood cells.

The body is smart, said Yang, associate professor of comparative medicine and of cellular & molecular physiology. It tries to protect against inflammation when fat builds up in the body. We discovered a key pathway that quenches inflammation caused by overnutrition.

In particular, the researchers found that OGT (O-GIcNAc transferase), an enzyme that activates GIcNAc signaling, was responsible for activating the bodys pro-inflammatory response by turning on or off a specific signaling pathway in macrophages.

The macrophage can be a good guy or a bad guy, Yang said. It becomes a bad guy in overnutrition, secreting a lot of inflammatory factors. In other contexts, its a good guy and has an anti-inflammatory effect. We found out that OGT tries to stop the macrophage from becoming a bad guy to stop the pro-inflammatory response.

Their finding suggests that OGT could be a target for new therapies to suppress inflammation and improve health.

The study also sheds light on the workings of glutamine and glucosamine, nutritional supplements recommended by doctors for arthritis and inflammation of the joints, Yang said. While researchers have known that these supplements promote O-GlcNAc signaling and reduce inflammation, they did not know how this process worked.

Our finding further implicates how glutamine and glucosamine suppress inflammation, Yang said.

Other members of the Yale research team include Dr. Gerald I. Shulman, Dr. Marie E. Robert, Rachel J. Perry, Yunfan Yang, Xiruo Li, Harding H. Luan, Bichen Zhang, Kaisi Zhang, Zongyu Li, Minnie Fu, Dongyan Zhang, Simeng Wang, Yuyang Liu, Joo Paulo Albuquerque, Qunxiang Ong, Rui Li, and Qi Wang.

Read more from the original source:
Yale researchers find on-off switch for inflammation related to overeating - Yale News

Novel tool to inducibly knockout genes at cellular resolution in plants – Mirage News

Genome editing techniques have revolutionized research in life sciences. The Mhnen group at the University of Helsinki took advantage of these techniques and developed a novel genetic tool for plant research that enables efficient generation of target gene knockouts in desired cell types and at desired times.

Most of the discoveries in the modern plant biology have originated from studies utilizing molecular biology or molecular genetic techniques. In this approach, mutation in a gene i.e. gene knockout reveals its role in a biological process. However, some genes are central players in plant physiology or development a mutation in these genes cause lethality or severe developmental defects. Typically, such mutants have several defects in their development and physiology, thus making it challenging to separate the primary defect from the secondary defects caused by the mutation.

To identify the primary defects of such, essential genes, researchers have developed various conditional gene manipulation systems. However, the challenge is, there are currently no genetic systems available to knockout a gene conditionally, completely or cell-type-specific manner. Such a system would enable identification of primary functions of the essential genes.

Research group led by Dr. Ari Pekka Mhnen is studying development of vascular cambium, a lateral meristem that produces wood in trees and in other plant species. Vascular cambium appears late in development, therefore knockouts in several essential genes cause strong phenotypes in plants long before the cambium has even been established. This makes the identification of the role of the essential genes in cambium development even more difficult than in younger part of plants.

To tackle the problem, Xin Wang, a PhD student in my lab decided to combine a tissue-specific inducible system developed earlier in my lab with the popular CRISPR-Cas9 genome editing system. With such a system, one could knockout genes in desired cells at desired times. Initially, I thought that the genome editing system might not be efficient enough to knockout target genes in the somatic cells. Luckily, he nevertheless decided to generate the system and test it in Arabidopsis thaliana. To my big surprise, the system worked efficiently and precisely in the targeted cells.

The inducible genome editing (IGE) system performed well with three different genes tested. These studies enabled the identification and confirmation of the precise function of the three genes in root development. The IGE system and these findings were published in Nature Plants. Additionally, beyond the published paper, the Mhnen lab has successfully tested the IGE system with several other target genes. Plasmids containing the IGE system has already been distributed to several other labs around the world, thus it is possible that the IGE system will be widely used within plant biology community. Perhaps, with help of IGE system, we will have better understanding how the essential genes function in plants.

Nature Plants: An inducible genome editing system for plants, doi: 10.1038/s41477-020-0695-2

Originally posted here:
Novel tool to inducibly knockout genes at cellular resolution in plants - Mirage News

How does research in biochemistry fit into the wider goals of the NIH? – Open Access Government

Established in 1962, the National Institute of General Medical Sciences (NIGMS) supports basic research that increases understanding of biological processes while also laying the foundation for advances in disease diagnosis, treatment, and prevention in the U.S. NIGMS is headed by Director Jon R. Lorsch who oversees the Institutes $2.6 billion budget, which supports this research.

NIGMS supports more than 3,000 investigators and 4,500 research grants around 11% of the total number of research grants funded by the National Institutes of Health (NIH) as a whole. Additionally, it supports around 26% of the National Research Training Award (NRSA) trainees who receive assistance from NIH. It is organised into divisions that support research and research training in a range of different fields.

From 2018 onwards, NIGMS reorganised into three scientific divisions specifically: Biophysics, Biomedical Technology, and Computational Biosciences (BBCB); Genetics and Molecular, Cellular and Developmental Biology (GMCDB); and Pharmacology, Physiology, and Biological Chemistry (PPBC).

The latter of these divisions supports a broad spectrum of state-of-the-art research aimed at improving the molecular-level understanding of fundamental biological processes and discovering approaches to their control. Just some of the goals of this supported research include an improved understanding of drug action and of anaesthesia; mechanisms underlying responses to drugs; new methods and targets for drug discovery; an enhanced understanding of biological catalysis; knowledge of metabolic regulation and fundamental physiological processes; and the integration and application of basic physiological, pharmacological, and biochemical research to clinical issues in anaesthesia, clinical pharmacology, and trauma and burn injury.

The division itself has two components: The Biochemistry and Bio-related Chemistry Branch and the Pharmacological and Physiological Sciences Branch.

It is important to recognise the fundamentals of each branches focal point and what their individual goals are. Understanding the interactions between molecules thats chemistry. And understanding the chemistry that occurs in living organisms, however thats biochemistry. Furthermore, understanding how medicines work in the body and finding ways to make them work better and more effectively thats pharmacology. Studies in these areas are currently focussing on areas such as:

How enzymes generate cellular energy and facilitate chemical reactions.

How medicines are processed inside the body.

What roles natural substances such as fats and sugars play in our bodies.

How a persons genetic makeup can influence a drugs effectiveness.

How to use chemistry to design new medicines.

The possibility of finding new uses for existing medicines.1

The Biochemistry and Bio-related Chemistry Branch supports basic research in the following areas:

Read the original post:
How does research in biochemistry fit into the wider goals of the NIH? - Open Access Government

Hematology Therapies Market Growth to Witness Uptrend with Robust Sales Volume – Cole of Duty

AMA Research have added latest edition of survey study on Global Hematology Therapies Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for Global Hematology Therapies Forecast till 2025*. Some are the key players taken under coverage for this study is Abbott Laboratories (United States), Bio-Rad Laboratories (United States), Roche (Switzerland), HORIBA (Japan), Beckman Coulter (United States), Bayer (Germany), Sysmex Corporation (Japan), Ortho Clinical Diagnostic (United States), Siemens Healthineers (Germany), Boule Diagnostics (Sweden), EKF Diagnostics (United Kingdom) and Mindray Medical (China)..

Free Sample Report + All Related Graphs & Charts @ https://www.advancemarketanalytics.com/sample-report/128606-global-hematology-therapies-market

Hematologic therapies represent a molecular understanding of the disease pathophysiology and treatment targeted precisely at the known aberration. Hematology includes the treatment of blood disorders and malignancies, like leukemia, hemophilia, lymphoma and sickle-cell anemia. Hematology is a branch of internal medicine that deals with the diagnosis, physiology, prognosis, pathology, etiology, treatment, and prevention of blood-related disorders. Hematologists focus mainly on lymphatic organs and bone marrow and may diagnose blood count irregularities or platelet irregularities.

Important Features that are under offering & key highlights of the report:

1) How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020?

Analyst at AMA are constantly gathering and conducting survey with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to evaluate study and market estimates. Due to lockdown different online medium and procedures are followed like Survey Monkey, LinkedIn Connections, and Email reach and industry forum to established industry viewpoint to garner rich insights for study. A special chapter in the study presents Impact Analysis of COVID-19 on Global Hematology Therapies Market along with tables and graphs related to various country and segments showcasing impact on growth trends.

2) Can list of players be customizing according to targeted regional geographies to match business objective?

Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are Abbott Laboratories (United States), Bio-Rad Laboratories (United States), Roche (Switzerland), HORIBA (Japan), Beckman Coulter (United States), Bayer (Germany), Sysmex Corporation (Japan), Ortho Clinical Diagnostic (United States), Siemens Healthineers (Germany), Boule Diagnostics (Sweden), EKF Diagnostics (United Kingdom) and Mindray Medical (China).. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography.

** List of companies covered may vary in the final report subject to Name Change / Merger & Acquisition Activity etc. based on the difficulty of survey since data availability needs to be confirmed by research team especially in case of privately held company. Up to 2 players can be added at no additional cost.

3) Can Market be broken down by different set of application and types?

Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.

** 3+ Additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of AMA based on the requirement shared and accordingly deliverable time will also be disclosed.

Enquire for customization in Report @https://www.advancemarketanalytics.com/enquiry-before-buy/128606-global-hematology-therapies-market

To comprehend Hematology Therapies market dynamics in the world mainly, the worldwide Hematology Therapies market is analyzed across major global regions. AMA also provides customized specific regional and country-level reports for the following areas.

Get Reasonable Discount on This Premium Report @ https://www.advancemarketanalytics.com/request-discount/128606-global-hematology-therapies-market

Major Highlights of TOC:

Chapter One: Market Overview

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD1000

Market Drivers, Market Challenges, Market Trends, Restraints & Opportunities, Post Covid Scenario

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Bargain Power

Chapter Five: Global Hematology Therapies, by Market Segmentation and Geography (value, volume**) (2014-2019) USD1400

by Type (Instruments, Consumable), Application (Physiology, Pathology, Etiology, Diagnosis, Treatment, Prognosis), Blood Disorder Type (Hemophilia, Leukemia, Lymphoma, Sickle-Cell Anemia, Others), End-User (Diagnostic Laboratories, Hospitals and Clinics, Academic Institutes, Research Laboratory, Others)

.

.

Global Hematology Therapies Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Hematology Therapies Manufacturers/Players Analysis USD1200

Competitive Landscape, Comparative Market Share Analysis (2018-2019), Peer Group Analysis (2019), BCG Matrix, Company Profile, Product/Service Offering Matrix

Chapter Seven: Global Hematology Therapies, by Market Segmentation and Region (value, volume**) (2020-2025) USD1400

Sections same as Chapter Five

Chapter Eight:Company profiles / Competitive Landscape [12 Players] USD1250

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicableActual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

AMA also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise section or region wise report like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)

AMA Research & Media LLP

Unit No. 429, Parsonage Road Edison, NJ

New Jersey USA 08837

Phone: +1 (206) 317 1218

[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

View post:
Hematology Therapies Market Growth to Witness Uptrend with Robust Sales Volume - Cole of Duty

COVID-19 Effect On Biostimulants Market Share and Development 2020 – Cole of Duty

Overview Of Biostimulants Industry 2020-2026:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Biostimulants Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Agricultural biostimulants include diverse formulations of compounds, substances and other products that are applied to plants or soils to regulate and enhance the crops physiological processes, thus making them more efficient. Biostimulants act on plant physiology through different pathways than nutrients to improve crop vigour, yields, quality and post-harvest shelf life/conservation.

Biostimulants Market competition by top manufacturers as follow: , Agri Life, Biostadt, Neophyll, Nakoda Biocontrols, Biotech International, India FarmCare, Miracle Organics Private, HCM Agro produts, Vijay Agro Industries, Arysta Life Science, VALAGRO, Leili, Acadian Seaplants, Kelpak, Grow More

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/11841

The global Biostimulants market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Acid-based BiostimulantsExtract-based Biostimulants

Market Segment by Applications, covers:Fruits & VegetablesTurf & OrnamentalsRow Crops

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/11841

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Biostimulants-Market-11841

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Visit link:
COVID-19 Effect On Biostimulants Market Share and Development 2020 - Cole of Duty

Swedish Healthcare Region to Realize Integrated Diagnostics – Expands IT Solution From Sectra With Digital Pathology – BioSpace

LINKPING, Sweden, June 29, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a digital pathology contract with Region Vstmanland in Sweden. The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department. Using the same system to store and view images and information from various diagnostic specialties enables integrated diagnostics, which is key for efficient cancer care.

"We are excited to take the next step in our digitization journey toward a truly integrated diagnostic workflow. It is important that we can scale our solution at our own pace and Sectra's solution allows this. We are also looking forward to equipping our pathologists with the tools that support us in our efforts to provide the best possible cancer care," says Jonas Cederberg, Chair of Department for Medical Diagnostics at Region Vstmanland.

With digital images of tissue samples rather than physical glass slides, pathologists can instantly access and share current and historical images and information from anywhere and at any time. Digital pathology provides pathologists with tools that are not available when using a microscope, which reduces variation between examinations and enables pathologists to spend their time on more advanced tasks. The digital solution also provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements. Furthermore, digital access facilitates second opinions, external reading resources, and specialist consultations.

Sectra's digital pathology solution will be integrated with Region Vstmanland's laboratory information system (LIS). This will provide pathologists with a complete overview of the patient history in one application and enable workflow orchestration to drive the workflow according to sub-specialties, rules and priorities. The solution's vendor-neutral approach also gave Region Vstmanland the freedom to select the scanner vendor of its choice.

Region Vstmanland is already using Sectra's solution for handling medical images within radiology, mammography, and clinical physiology. The solution will now also include approximately 10,000 pathology examinations per year, with the opportunity to gradually increase usage. The agreement to expand the existing contract was signed in May 2020.

Sectra's enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Read more about Sectra's enterprise imaging solution and why Sectra PACS is ranked "Best in KLAS" for seven consecutive years at https://medical.sectra.com/.

About SectraSectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linkping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2019/2020 fiscal year totaled SEK 1,661 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit https://sectra.com/.

CONTACT:

For further information, please contact:Dr. Torbjrn KronanderCEO and President Sectra AB+46-(0)705-23-52-27

Marie Ekstrm TrgrdhExecutive Vice President Sectra AB and President Sectra Imaging IT Solutions+46-(0)708-23-56-10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/swedish-healthcare-region-to-realize-integrated-diagnostics-expands-it-solution-from-sectra-with-dig,c3142885

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/swedish-healthcare-region-to-realize-integrated-diagnostics---expands-it-solution-from-sectra-with-digital-pathology-301084853.html

SOURCE Sectra

Company Codes: Stockholm:SECTB, ISIN:SE0012853661, RICS:SECTB.ST, LSE:0A0L, Stuttgart:ECRH

Link:
Swedish Healthcare Region to Realize Integrated Diagnostics - Expands IT Solution From Sectra With Digital Pathology - BioSpace